IL1B and chronic kidney disease: Suppression of IL-1β has been further shown to attenuate CKD progression in obese and diabetic db/db mice as reflected by milder GFR decline and reduced renal expression of kidney damage biomarkers including the neutrophil gelatinase-associated lipocalin (NGAL) (108, 109).